"I am honored to co-chair this event alongside David, especially as it is the first event of its kind and is the beginning of introducing Digital Therapeutics to the broader healthcare community," said Dthera Sciences CEO, Edward Cox. "I think we may look back at this event as a very unique gathering of people that will go on to be the leaders in this new field of medicine."

Taking place on February 27th-28th, this summit is aimed to define the current and future landscape of this rapidly emerging industry.

The event is the first ever gathering of leaders in this fast-growing industry and, in addition to Mr. Cox and Mr. Klein, a number of other notable speakers will be present including:

Sean Duffy, CEO, Omada Health

Alex Waldron, CCO, Pear Therapeutics

Eddie Martucci, CEO, Akili Interactive Labs

Kevin McRaith, CEO, WellDoc

Debbie Profit, VP, IT, Otsuka Pharmaceuticals

Bozidar Jovecevic, VP, Global Head of Digital Medicines, Sanofi

Seth Feuerstein, CIO & CMO, Digital Innovation, Magellan Health

Albert Chan, VP, Chief of Digital Patient Experience, Sutter Health

John Spinale, General Partner, Jazz Venture Partners

Aaron Nelson, General Partner, dRx Capital

About the Digital Therapeutics and Digital Medicine Summit, DTxDM

The Digital Therapeutics & Digital Medicine Summit (a Grey Green Media event, www.greygreenmedia.com) provides the industry's first dedicated platform for digital therapeutic/medicine companies, pharma, investors and solution-providers to come together to advance this next generation of validated digital healthcare. Constructed with industry leaders, the inaugural DTxDM Summit (February 27th-28th, San Jose, CA) will be showcasing the latest advancements, hosting crucial discussions and providing unprecedented networking opportunities for the pioneers and future adopters of digital therapeutics and digital medicine. This event is the first in the series, with the next summit, DTx East, taking place on September 25th-26th in Boston, MA.

About Dthera Sciences

Dthera Sciences, based in San Diego, CA, is a publicly-traded digital therapeutics company focused on developing innovative digital 'quality of life' therapies for neurodegenerative diseases and other chronic conditions. The Company's lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to improve quality of life in patients with Alzheimer's disease and Dementia. For more information, please visit www.dthera.com and www.reminx.com

About Digital Therapeutics

Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors' and nurses' care, changing patient behavior, and most importantly, reducing cost of care.